drugset / Trial / NCT05970679

Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A

NCT05970679

Phase 3 Completed 252 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double blind, Parallel, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A in Patient with primary Hypercholesterolemia or Mixed Dyslipidemia

Timeline

Start
2022-08-17
Primary completion
2023-04-13
Completion
2023-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 5 mg Oral
Subject Atorvastatin Small molecule 10 mg Oral
Subject Ezetimibe Unknown 10 mg Oral

Indications